Nicotine Steering Committee
“The FDA is envisioning a world where cigarettes can no longer create or sustain addiction, and where adults who still need or want nicotine can get it from alternative and less harmful sources.” Scott Gottlieb, M.D., October 19, 2017
Established September 2017, the FDA Nicotine Steering Committee (NSC) is a forum for developing and implementing nicotine policy and regulation. The Committee comprises senior leaders from the Center for Drug Evaluation and Research (CDER), the Center for Tobacco Products (CTP), and the Office of the Commissioner. The Committee ensures alignment of FDA’s centers and facilitates consensus and development of unified FDA positions on cross-cutting issues. The primary focus of the Committee is on the use of therapeutic nicotine for combustible tobacco product cessation.
More Information
- Broad Agency Announcement - Facilitate Development of Drug Therapies for Youth Tobacco Cessation
- FRN: Nicotine Steering Committee; Establishment of a Public Docket, Request for Comments
- FRN: The Food and Drug Administration's Approach to Evaluating Nicotine Replacement Therapies; Part 15 Public Hearing
- Public Meeting on FDA Approach to Evaluating Nicotine Replacement Therapies
- FDA Voices: Advancing Medicinal Nicotine Replacement Therapies as New Drugs: A new step in FDA's comprehensive approach to tobacco and nicotine
- SMG 2010.20: FDA Nicotine Steering Committee
- Fact or Fiction: What to Know About Smoking Cessation and Medications
- Youth Tobacco Cessation: Science and Treatment Strategies public workshop
- FDA Public hearing on Eliminating Youth Electronic Cigarette and Other Tobacco Product Use: The Role for Drug Therapies